Aktive Positionen von Ruben J. Boado
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2004 | - |
| Gründer | 01.01.2004 | - |
Karriereverlauf von Ruben J. Boado
Ehemalige bekannte Positionen von Ruben J. Boado
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| University of California, Los Angeles | Corporate Officer/Principal | - | - |
Ausbildung von Ruben J. Boado
| Universidad de Buenos Aires | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Argentinien | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Doctorate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
- Börse
- Insiders
- Ruben J. Boado
- Erfahrung
